VivoSeq
Other

Immune Checkpoint Blockade

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Immune Checkpoint Blockade is an early-stage landscape with 0 programs across 1 company. The most active players are Moderna.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Moderna logo

Moderna

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Active, not recruiting2 · 33%
Withdrawn2 · 33%
Recruiting1 · 17%
Terminated1 · 17%

Clinical Trials

Trial Activity

6 trials

Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Recruiting·VVall d'Hebron Institute of Oncology·Phase 1·NCT05141474·10 enrolled
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
Active, not recruiting·Moderna logoModerna·Phase 1·NCT06880549·57 enrolled
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
Active, not recruiting·—·Phase 1/2·NCT04454528·27 enrolled
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Terminated·—·Phase 1/2·NCT04214418·27 enrolled
Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT
Withdrawn·WWashington University School of Medicine·Phase 2·NCT04271436
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Withdrawn·GGritstone bio, Inc.·Phase 2·NCT05456165

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)